NewAmsterdam Pharma: Late-Stage Obicetrapib Momentum, Regulatory Catalysts, and Strong Cash Position Underpin Buy Rating

NewAmsterdam Pharma Company, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $52.00 price target.

Joseph Pantginis has given his Buy rating due to a combination of factors tied to NewAmsterdam Pharma’s lead asset, obicetrapib, and the company’s overall strategic positioning. He points to the ongoing Phase 3 PREVAIL cardiovascular outcomes trial, along with REMBRANDT and RUBENS, as evidence that obicetrapib has meaningful potential not only in LDL-C reduction but also in broader cardiometabolic and neuroinflammatory settings. Pantginis emphasizes that PREVAIL’s design, early blinded MACE trends consistent with prior Phase 3 studies, and favorable biomarker effects (including ApoB and Lp(a)) collectively support the likelihood of a positive readout by year-end 2026 and a broad cardiovascular risk reduction label. He also highlights that NewAmsterdam is exploring additional upside from combination regimens (such as with PCSK9 inhibitors) and expansion into new indications like type 2 diabetes, thereby widening the future revenue opportunity.

Furthermore, Pantginis underscores the company’s solid financial footing, noting the roughly $729 million in cash, which management believes is sufficient to fund operations through the PREVAIL readout and support a potential U.S. launch. He views the acceptance of obicetrapib monotherapy and fixed-dose combination MAAs by the EMA and the expectation of European approvals in the second half of 2026 as key value drivers. The completion of PREVAIL enrollment in over 9,500 ASCVD patients already on maximally tolerated lipid-lowering therapy, together with positive Phase 3 BROADWAY, TANDEM, and BROOKLYN results, reinforces his conviction in obicetrapib’s risk-benefit profile. In Pantginis’s view, this mix of late-stage clinical momentum, regulatory catalysts, and robust balance sheet justifies a Buy rating on NewAmsterdam Pharma’s shares.

In another report released on January 5, Citi also maintained a Buy rating on the stock with a $55.00 price target.